Silo Pharma, Inc. (SILO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to treat rare diseases, including PTSD, depression, Alzheimer's, and Parkinson's. The company operates as a smaller reporting company and is incorporated in Nevada. This report covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $18,025 | $36,051 | $36,051 |
| Net Loss | $(931,779) | $(1,733,446) | $(1,919,347) |
| Loss Per Share (Basic/Diluted) | $(0.31) | $(0.59) | $(0.61) |
| Cash and Cash Equivalents | $4,506,300 (as of June 30, 2024) | ||
| Short-Term Investments | $3,102,240 (as of June 30, 2024) | ||
| Working Capital | $6,405,949 (as of June 30, 2024) | ||
| Accumulated Deficit | $(12,605,257) (as of June 30, 2024) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses for the six months ended June 30, 2024, were $1,915,419, a slight decrease of 1.9% compared to $1,951,602 in the prior year period.
- Research & Development (R&D): Increased significantly by 132.3% to $774,889 (YTD 2024) from $333,632 (YTD 2023), driven by increased costs for investigator-sponsored studies with UCSF, UMB, and Columbia University.
- Professional Fees: Decreased by 31.5% to $641,067, primarily due to reduced legal and consulting fees, partially offset by increased investor relations costs.
- Selling, General & Administrative (SG&A): Decreased by 62.2% to $114,931, largely attributed to a $214,967 reduction in Delaware franchise taxes following the company's reincorporation in Nevada.
- Other Income: Net other income for the six months ended June 30, 2024, was $148,841, a significant improvement from a net expense of $(877) in the prior year. This was primarily due to the absence of a $166,034 penalty for early termination of a certificate of deposit incurred in 2023.
- Financing Activity: The company raised net proceeds of approximately $1.67 million in June 2024 through the sale of common stock and pre-funded warrants, compared to no equity financing in the same period in 2023.
Guidance, Outlook, and Risks
- Product Pipeline: The company is advancing four product candidates: SPC-15 (PTSD/anxiety), SP-26 (chronic pain/fibromyalgia), SPC-14 (Alzheimer's), and SPU-16 (Multiple Sclerosis).
- SPC-15: A pre-IND briefing package was submitted to the FDA on June 4, 2024. An exclusive license for SPC-15 was executed with Columbia University effective June 28, 2024.
- Liquidity: Management believes current cash and short-term investments ($7.6 million combined) are sufficient to meet obligations for at least the next 12 months. The company maintains positive working capital of $6.4 million.
- Recent Capital Raises:
- June 2024: Sold 883,395 shares and pre-funded warrants for gross proceeds of ~$2.0 million.
- July 2024 (Subsequent Event): Sold 763,638 shares for gross proceeds of ~$2.1 million, closing July 22, 2024.
- Risks:
- Going Concern: While liquidity is currently sufficient, the company has an accumulated deficit of $12.6 million and relies on future financing or revenue generation.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, citing a lack of segregation of duties and inadequate system controls due to limited resources.
- Regulatory: Development of psychedelic-based therapies involves significant regulatory uncertainty and reliance on FDA/DEA approvals.
Key Facts for Investor Verification
- Revenue Concentration: 100% of revenue for the six months ended June 30, 2024, came from a single licensee (Aikido Pharma Inc.).
- License Commitments: The company has significant future payment obligations under research and license agreements, including approximately $1.88 million due in 2025 under sponsored study agreements.
- Stock Repurchases: The company repurchased 102,855 shares for $173,113 during the first six months of 2024 under an extended stock repurchase plan.
- Intangible Assets: A new intangible asset of $247,400 was recorded in Q2 2024 related to the exclusive license agreement with Columbia University.
- Subsequent Equity Issuance: Verify the impact of the July 2024 registered direct offering (763,638 shares) on share count and dilution.